A multicenter open-label non-randomized phase II study of elsamitrucin (SPP 28090) in patients with relapsed or refractory non-Hodgkin's lymphoma
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2014
At a glance
- Drugs Elsamitrucin (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 23 Jun 2009 Additional lead trial investigator (Mohrbacher A) identified as reported by ClinicalTrials.gov.
- 18 Jan 2008 Status change from recruiting to completed.
- 22 Oct 2005 New trial record.